It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Shigella is a leading cause of moderate to severe diarrhea worldwide and of diarrhea-associated deaths in children under 5 years of age in low-and middle-income countries. A vaccine against shigellosis is in high demand. SF2a-TT15, a synthetic carbohydrate-based conjugate vaccine candidate against Shigella flexneri 2a (SF2a) was found safe and strongly immunogenic in adult volunteers. Here, SF2a-TT15 at 10 µg oligosaccharide (OS) vaccine dose is shown to induce a sustained immune response in magnitude and functionality in the majority of volunteers followed up 2 and 3 years post-vaccination. High levels of either one of the humoral parameters as well as the number of specific-IgG memory B-cells determined 3 months after vaccination were good predictors of the durability of the immune response. This study is the first to examine the long-term durability of antibody functionality and memory B-cell response induced by a Shigella vaccine candidate.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tel Aviv University, Ramat Aviv, School of Public Health, Sackler Faculty of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
2 Tel Aviv University, Ramat Aviv, School of Public Health, Sackler Faculty of Medicine, Tel Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546); Clinical Microbiology Laboratory, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922)
3 Institut Pasteur, Université Paris Cité, CNRS UMR3523, Unité de Chimie des Biomolécules, Paris, France (GRID:grid.12136.37)
4 Institut Pasteur, Innovation Lab. Vaccines, Paris, France (GRID:grid.428999.7) (ISNI:0000 0001 2353 6535)